Table 2 Sensitivity analyses for the MACE surrogate endpoint using alternative grouping strategy: grouping by various actual and synthetic geographical regions
From: Surrogate endpoint evaluation using data from one large global randomized controlled trial
Geographical regions | CV death | All-cause death |
|---|---|---|
R2group (95% CI) | ||
Approach 1 | 0.95 (0.76, 1.00) | 0.77 (0.00, 1.00) |
Group 1 (North America): CA, US | ||
Group 2 (Europe): AT, BE, CZ, DE, DK, ES, FI, FR, GB, GR, IE, IL, IT, NL, NO, PL, RO, RS, SE | ||
Group 3 (Asia): CN, IN, KR, TW | ||
Group 4 (Rest of the World): AE, AU, BR, MX, RU, TR, ZA | ||
Approach 2 | 0.85 (0.58, 1.00) | 0.53 (0.00, 1.00) |
Group 1 (Canada): CA | ||
Group 2 (United States of America): US | ||
Group 3 (Mid- and Northern Europe): AT, BE, DE, DK, FI, FR, GB, IE, IL, NL, NO, SE | ||
Group 4 (Eastern Europe: CZ, PL, RO, RS | ||
Group 5 (Southern Europe): ES, GR, IT | ||
Group 6 (Asia): CN, IN, KR, TW | ||
Group 7 (Rest of the World): AE, AU, BR, MX, RU, TR, ZA | ||
Approach 3 | 0.77 (0.47, 1.00) | 0.32 (0.00, 0.89) |
Group 1: (Canada): CA | ||
Group 2: (United States of America): US | ||
Group 3: (Mid Europe) AT, BE, DE, FR, IL, NL | ||
Group 4: (Eastern Europe) CZ, PL, RO, RS | ||
Group 5: (Southern Europe): ES, GR, IT | ||
Group 6: (Northern Europe): DK, FI, NO, SE | ||
Group 7: (United Kingdom and Ireland): GB, IE | ||
Group 8: (Asia): CN, IN, KR, TW | ||
Group 9: (Rest of the World): AE, AU, BR, MX, RU, TR | ||
Group 10: (Southern Africa): ZA | ||